Sputnik V production starts in India at Panacea Biotec's Baddi unit

First batch to be shipped to Gamaleya for quality control; Panacea to produce 100 mn doses

The manufacture in India of Sputnik V vaccine has begun with Panacea Biotec announcing the launch of production on Monday.

The first batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control, noted the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund.

“Full-scale production of the vaccine is due to start this summer. The company’s facilities comply with GMP standards and are prequalified by WHO,” it added. Panacea will produce 100 million doses of Sputnik V.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said: “Launch of production in India